Pregled bibliografske jedinice broj: 869839
Terapija muptiple skleroze – od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida
Terapija muptiple skleroze – od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida // Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva, 73 (2017), 177-190 (podatak o recenziji nije dostupan, pregledni rad, stručni)
CROSBI ID: 869839 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Terapija muptiple skleroze – od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida
(Therapy of multiple sclerosis – of conventional therapy and monoclonal antibodies to cannabinoids)
Autori
Rajić Džolić, Zrinka ; Šipicki, Sara ; Perković, Ivana
Izvornik
Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva (0014-8202) 73
(2017);
177-190
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni
Ključne riječi
multipla skleroza, kortikosteroidi, lijekovi koji mijenjaju tijek bolesti, monoklonsko protutijelo, kanabinoid
(multiple sclerosis, corticosteroids, disease modifying therapy, monoclonal antibody, cannabinoid)
Sažetak
Multiple sclerosis is an autoimmune neurodegenerative disease, with inflammation and demyelination in the central nervous system, which results in diff erent neurological symptoms. The disease is usually diagnosed as a relapsing-remittent multiple sclerosis (85 %), which is characterized by acute attacks followed by recovery. Here we describe drugs used in the therapy/management of multiple sclerosis. In the acute phase new symptoms appear or the current neurological status worsens. The standard therapy consists of high doses of methylprednizolone, which is efficacious and usually leads to a quick recovery. Disease-modifying drugs are used to reduce the frequency of relapses and to slow the progression of disability. The classical first line drugs are interferon-b and glatiramer acetate. Other drugs include fingolimod, teriflunomid, dimethylfumarate, mitoxantron, natalizumab, alemtuzumab and daclizumab. Immunosupressive agents are also used in the therapy. Th e third class of drugs are used to alleviate the symptoms of the disease. Here we describe the benefi tial eff ects of cannabinoids in more detail.
Izvorni jezik
Hrvatski
Znanstvena područja
Farmacija
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus